Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials
Diabetologia · 2024-07 · 67 (7) · 1206-1222
DOI: 10.1007/s00125-024-06144-1 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Diabetologia, online erschienen am 13.04.2024. Verfasst von Thomas Karagiannis und 9 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Research and Evidence-Based Medicine Unit, Second Medical Department, Aristotle University of Thessaloniki, Thessaloniki, Greece. tkaragian@…. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Hypoglycemic Agents, Glucagon-Like Peptides, Randomized Controlled Trials as Topic. Die Arbeit wurde bisher 98-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Aristotle University of Thessaloniki.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aims/hypothesis We conducted a systematic review and network meta-analysis to compare the efficacy and safety of s.c. administered tirzepatide vs s.c. administered semaglutide for adults of both sexes with type 2 diabetes mellitus. Methods We searched PubMed and Cochrane up to 11 November 2023 for RCTs with an intervention duration of at least 12 weeks assessing s.c. tirzepatide at maintenance doses of 5 mg, 10 mg or 15 mg once weekly, or s.c. semaglutide at maintenance doses of 0.5 mg, 1.0 mg or 2.0 mg once weekly, in adults with type 2 diabetes, regardless of background glucose-lowering treatment. Eligible trials compared any of the specified doses of tirzepatide and semaglutide against each other, placebo or other glucose-lowering drugs. Primary outcomes were changes in HbA 1c and body weight from baseline. Secondary outcomes were achievement of HbA 1c target of ≤48 mmol/mol (≤6.5%) or
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Research and Evidence-Based Medicine Unit, Second Medical Department, Aristotle University of Thessaloniki, Thessaloniki, Greece. tkaragian@auth.gr.
- Diabetes Centre, Second Medical Department, Aristotle University of Thessaloniki, Thessaloniki, Greece. tkaragian@auth.gr.
- Clinical Research and Evidence-Based Medicine Unit, Second Medical Department, Aristotle University of Thessaloniki, Thessaloniki, Greece.
- Diabetes Centre, Second Medical Department, Aristotle University of Thessaloniki, Thessaloniki, Greece.
- School of Medicine, Faculty of Health Science, Aristotle University of Thessaloniki, Thessaloniki, Greece.
- Harris Manchester College, University of Oxford, Oxford, UK.
Förderung
- Aristotle University of Thessaloniki
Zitieren
APA
Karagiannis, T., Malandris, K., Avgerinos, I., Stamati, A., Kakotrichi, P., Liakos, A., Vasilakou, D., Kakaletsis, N., Tsapas, A., & Bekiari, E. (2024). Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials. Diabetologia, 67(7), 1206-1222. https://doi.org/10.1007/s00125-024-06144-1
Vancouver
Karagiannis T, Malandris K, Avgerinos I, Stamati A, Kakotrichi P, Liakos A, et al. Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials. Diabetologia. 2024;67(7):1206-1222. doi:10.1007/s00125-024-06144-1
BibTeX
@article{Karagiannis2024,
author = {Karagiannis, Thomas and Malandris, Konstantinos and Avgerinos, Ioannis and Stamati, Athina and Kakotrichi, Panagiota and Liakos, Aris and Vasilakou, Despoina and Kakaletsis, Nikolaos and Tsapas, Apostolos and Bekiari, Eleni},
title = {Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials},
journal = {Diabetologia},
year = {2024},
volume = {67},
number = {7},
pages = {1206--1222},
doi = {10.1007/s00125-024-06144-1}
}
EUVIMED